Clinical trial · Interventional
Interleukin-2 Plus Bryostatin 1 in Treating Patients With Melanoma or Kidney Cancer
Phase IA/IB Trial of Modulation of the Biological Response to Interleukin-2 (IL-2) With Bryostatin 1 (BRYO; NSC 339555)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Interleukin-2 may stimulate a person's white blood cells to kill tumor cells. Combining bryostatin 1 with interleukin-2 may kill more tumor cells. PURPOSE: Randomized phase I trial to study the effectiveness of interleukin-2 plus bryostatin 1 in treating patients who have melanoma or kidney cancer that cannot be removed during surgery.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Kidney Cancer | Malignant Kidney Neoplasm | CURATED_EXACT | 0.92 |
| Melanoma (Skin) | Melanoma | ONTOLOGY_EXACT | 0.85 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| aldesleukin | Biological | Aldesleukin | ALIAS |
| bryostatin 1 | Drug | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 120 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Histologically or cytologically confirmed cutaneous or mucosal melanoma or renal cell carcinoma * Unresectable disease * No known uncontrolled CNS metastases * CNS metastases allowed only if recently irradiated or known to be controlled PATIENT CHARACTERISTICS: Age: * 18 and over Performance status: * ECOG 0-1 Life expectancy: * Not specified Hematopoietic: * Hemoglobin at least 8 g/dL * WBC at least 3,000/mm\^3 * Platelet count at least 100,000/mm\^3 * Absolute lymphocyte count at least 1,000/mm\^3 Hepatic: * Total bilirubin no greater than 1.5 mg/dL OR * Conjugated bilirubin no greater than 0.3 mg/dL * AST no greater than 2.5 times upper limit of normal Renal: * Creatinine no greater than 2 mg/dL Cardiovascular: * No myocardial infarction within the past 6 months * No uncontrolled hypertension, angina, or congestive heart failure Other: * Not pregnant or nursing * Fertile patients must use effective contraception during and for 3 months after study * No known intolerance to acetaminophen * No primary or secondary immunodeficiency * No other condition that would preclude study PRIOR CONCURRENT THERAPY: Biologic therapy: * Not specified Chemotherapy: * Not specified Endocrine therapy: * At least 1 month since prior topical, systemic, or inhaled corticosteroids * No concurrent topical, systemic, or inhaled corticosteroids Radiotherapy: * See Disease Characteristics Surgery: * Not specified
References
Publications (0)
Data not yet available